{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:02:43Z","timestamp":1789729363680,"version":"4.0.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Therapeutic enoxaparin was associated with a greater than threefold increased risk of major ICH in patients with glioma. The PANWARDS risk score was a sensitive predictor of major ICH in glioma.<\/jats:p>","DOI":"10.1182\/blood-2017-02-767285","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T21:10:25Z","timestamp":1493845825000},"page":"3379-3385","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":96,"title":["Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-3131","authenticated-orcid":false,"given":"Charlene","family":"Mantia","sequence":"first","affiliation":[{"name":"Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik J.","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneka","family":"Puligandla","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffin M.","family":"Weber","sequence":"additional","affiliation":[{"name":"Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center and Center for Biomedical Informatics, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-6893","authenticated-orcid":false,"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111822213864900_B1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1227\/00006123-198204000-00004","article-title":"Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance","volume":"10","author":"Wakai","year":"1982","journal-title":"Neurosurgery"},{"issue":"11","key":"2019111822213864900_B2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","article-title":"Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study","volume":"162","author":"Heit","year":"2002","journal-title":"Arch Intern Med"},{"issue":"suppl 1","key":"2019111822213864900_B3","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0049-3848(16)30100-1","article-title":"Intracranial hemorrhage in cancer patients treated with anticoagulation","volume":"140","author":"Weinstock","year":"2016","journal-title":"Thromb Res"},{"issue":"4","key":"2019111822213864900_B4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111822213864900_B5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111822213864900_B6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","article-title":"Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"issue":"4","key":"2019111822213864900_B7","doi-asserted-by":"crossref","first-page":"e62286","DOI":"10.1371\/journal.pone.0062286","article-title":"Volume quantification of acute infratentorial hemorrhage with computed tomography: validation of the formula 1\/2ABC and 2\/3SH","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"2019111822213864900_B8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.STR.24.7.987","article-title":"Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality","volume":"24","author":"Broderick","year":"1993","journal-title":"Stroke"},{"issue":"4","key":"2019111822213864900_B9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111822213864900_B10","first-page":"87","article-title":"Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism","volume":"3","author":"Khoury","year":"2016","journal-title":"Neuroncol Prac"},{"issue":"7","key":"2019111822213864900_B11","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/j.1538-7836.2012.04766.x","article-title":"Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier","volume":"10","author":"Campigotto","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"446","key":"2019111822213864900_B12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"2019111822213864900_B13","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","article-title":"Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban; the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"issue":"2","key":"2019111822213864900_B14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111822213864900_B15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"25","key":"2019111822213864900_B16","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111822213864900_B17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"8","key":"2019111822213864900_B18","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1212\/01.wnl.0000208400.08722.7c","article-title":"Long-term mortality after intracerebral hemorrhage","volume":"66","author":"Flaherty","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"2019111822213864900_B19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"issue":"2","key":"2019111822213864900_B20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"issue":"3","key":"2019111822213864900_B21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"issue":"1","key":"2019111822213864900_B22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Ru\u00edz-Gim\u00e9nez","year":"2008","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111822213864900_B23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111822213864900_B24","first-page":"4309","article-title":"Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients","volume":"29","author":"Pan","year":"2009","journal-title":"Anticancer Res"},{"key":"2019111822213864900_B25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","article-title":"Recurrent venous thromboembolism in glioblastoma","volume":"137","author":"Edwin","year":"2016","journal-title":"Thromb Res"},{"issue":"6","key":"2019111822213864900_B26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.43.6.1111","article-title":"Complications of therapy for venous thromboembolic disease in patients with brain tumors","volume":"43","author":"Levin","year":"1993","journal-title":"Neurology"},{"issue":"16","key":"2019111822213864900_B27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jacc.2014.01.058","article-title":"Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk","volume":"63","author":"Muriel","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2019111822213864900_B28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11060-015-1805-2","article-title":"Venous thromboembolism (VTE) and glioblastoma","volume":"124","author":"Yust-Katz","year":"2015","journal-title":"J Neurooncol"},{"issue":"1","key":"2019111822213864900_B29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1160\/TH11-06-0423","article-title":"Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism [published correction appears in Thromb Haemost. 2012;107(4):801]","volume":"107","author":"Marchena","year":"2012","journal-title":"Thromb Haemost"},{"issue":"9","key":"2019111822213864900_B30","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/jth.12651","article-title":"Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials","volume":"12","author":"Liew","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111822213864900_B31","first-page":"1268","article-title":"Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study","volume":"114","author":"van Es","year":"2015","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111822213864900_B32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","article-title":"Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants","volume":"73","author":"Purrucker","year":"2016","journal-title":"JAMA Neurol"},{"issue":"11","key":"2019111822213864900_B33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"issue":"21","key":"2019111822213864900_B34","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"2019111822213864900_B35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/25\/3379\/1364321\/blood767285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/25\/3379\/1364321\/blood767285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:21:59Z","timestamp":1574115719000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/25\/3379\/107610\/Predicting-the-higher-rate-of-intracranial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":35,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2017,6,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-02-767285","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}